Novocure Ltd (Nasdaq:NVCR)
June 13th, 2019
Amidst rising markets Novocure Ltd rose $1.28 Thursday, a 2.29% jump, closing at $57.06. Furthermore it hit a new 52 week high of $57.82. The stock continues to trade well at 119.29% of its 52 week low of $26.02.
NVCR outperformed the rest of the Healthcare sector which went down -0.11% today.
Results from 6 analysts suggest that Novocure Ltd could decline somewhat (-2.90%), while Finbox has calculated (with high uncertainty) a fair value price of $62.36.
The market sectors were mixed Thursday with a majority of the sectors trending up. Energy saw the biggest increase of the day (1.25%), while the Healthcare sector saw the biggest drop (-0.11%). Information Technology has seen the biggest year-to-date gain of 23.06%.
Utilities saw the biggest turn-around compared to its 5-day performance (-0.31%), as it went up by 0.15%. Healthcare saw a turn-around from its 5-day performance of 2.18% trading down -0.11%.
- Energy, up 1.25%.
- Communication Services, up 1.14%.
- Consumer Discretionary, up 0.90%.
- Materials, up 0.58%.
- Industrials, up 0.54%.
- Financials, up 0.23%.
- Information Technology, up 0.22%.
- Utilities, up 0.15%.
- Consumer Staples, up 0.11%.
- Real Estate, up 0.09%.
- Healthcare, down -0.11%.
Novocure Ltd Info
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. The company markets Optune, a Tumor Treating Fields delivery system for use as a monotherapy treatment for adult patients with glioblastoma. It is also developing products that are in Phase II pilot and Phase III pivotal trials for brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, liver cancer, and mesothelioma. The company markets its products in the European Union, Japan, and internationally. NovoCure Limited was founded in 2000 and is based in Saint Helier, Jersey.
All amounts in USD unless otherwise indicated
Media Gazelle Inc (MG), a Nevada Corporation, owns and operates the online brand US Tribune News. MG does not offer financial advise, and is not a registered broker/dealer/analyst/adviser, holds no investment licenses, and may not sell, offer to sell or offer to buy any security. MG’s market updates, news are not a solicitation or recommendation to buy, sell or hold securities. MG shall not be held liable for any investment losses you may incur by using the information provided, this includes you trading the stocks mentioned on our sites. We recommend you talk to a financial adviser before trading any securities or taking any action based upon information on this site. MG does not guarantee the accuracy of the article.